AiCuris Anti-infective Cures AG

AiCuris is a German biopharmaceutical company specializing in the discovery, research, and development of novel, resistance-breaking antiviral and antibacterial agents. The company focuses on addressing the critical unmet medical needs of immunocompromised patients, particularly those suffering from life-threatening infections in transplant and nephrology settings. Following its acquisition by Asahi Kasei in April 2026, AiCuris operates as a key component of the parent company's specialty pharmaceutical platform. Its portfolio includes the commercialized product Prevymis® (letermovir), which is out-licensed to Merck & Co., and a robust clinical-stage pipeline led by the helicase-primase inhibitor pritelivir.